Vaccines based on structure-based design provide protection against infectious diseases

References

• Rezza G, Nicoletti L, Angelini R et al; CHIKV study group. Infection with chikungunya virus in Italy: an outbreak in a temperate region. Lancet 370, 1840–1846 (2007).
   PubMed Web of Science ®Google Scholar
• González-Parra G, Arenas AJ, Aranda DF, Segovia L. Modeling the epidemic waves of AH1N1/09 influenza around the world. Spat. Spatiotemporal Epidemiol. 2, 219–226 (2011).
   PubMedGoogle Scholar
• Vivancos R, Keenan A, Sopwith W et al. Norovirus outbreak in a cruise ship sailing around the British Isles: investigation and multi-agency management of an international outbreak. J. Infect. 60, 478–485 (2010).
   PubMedGoogle Scholar
• Doménech-Sánchez A, Juan C, Pérez JL, Berrocal CI. Unmanageable norovirus outbreak in a single resort located in the Dominican Republic. Clin. Microbiol. Infect. 17, 952–954 (2011).
   PubMedGoogle Scholar
• de Quadros CA, Carrasco P, Olivé JM. The desired field-performance characteristics of new improved vaccines for the developing world. Int. J. Technol. Assess Health Care 10, 65–70 (1994).
   PubMedGoogle Scholar
• Fenner F, Henderon DA, Arita I, Jezek Z, Ladnyi ID. Smallpox and its Eradication. World Health Organization, Geneva (1988).
   Google Scholar
• Horzinek MC. Rinderpest: the second viral disease eradicated. Vet. Microbiol. 149, 295–297 (2011).
   PubMedGoogle Scholar
• Plowright W, Ferris RD. Studies with rinderpest virus in tissue culture. The use of attenuated culture virus as a vaccine for cattle. Res. Vet. Sci. 3, 172–182 (1962).
   Google Scholar
• Sztein MB. Cell-mediated immunity and antibody responses elicited by attenuated Salmonella enterica Serovar Typhi strains used as live oral vaccines in humans. Clin. Infect. Dis. 45( Suppl. 1), S15–S19 (2007).
   PubMed Web of Science ®Google Scholar
• Amorij JP, Huckriede A, Wilschut J, Frijlink HW, Hinrichs WL. Development of stable influenza vaccine powder formulations: challenges and possibilities. Pharm. Res. 25, 1256–1273 (2008).
   PubMed Web of Science ®Google Scholar
• Baxter D. Specific immunization issues in the occupational health setting. Occup. Med. 57, 557–563 (2007).
   Google Scholar
• Wei H, Huang D, Fortman J, Wang R, Shao L, Chen ZW. Coadministration of cidofovir and smallpox vaccine reduced vaccination side effects but interfered with vaccine-elicited immune responses and immunity to monkeypox. J. Virol. 83, 1115–1125 (2009).
   PubMed Web of Science ®Google Scholar
• Levine MM, Tacket CO, Sztein MB. Host-Salmonella interaction: human trials. Microbes Infect. 3, 1271–1279 (2001).
   PubMed Web of Science ®Google Scholar
• Mitsuyama M, Igarashi K, Kawamura I, Ohmori T, Nomoto K. Difference in the induction of macrophage interleukin-1 production between viable and killed cells of Listeria monocytogenes. Infect. Immun. 58, 1254–1260 (1990).
   PubMedGoogle Scholar
• Biesova Z, Miller MA, Schneerson R et al. Preparation, characterization, and immunogenicity in mice of a recombinant influenza H5 hemagglutinin vaccine against the avian H5N1 A/Vietnam/1203/2004 influenza virus. Vaccine 27, 6234–6238 (2009).
   PubMed Web of Science ®Google Scholar
• Hu AY, Tseng YF, Weng TC et al. Production of inactivated influenza H5N1 vaccines from MDCK cells in serum-free medium. PLoS ONE 6, e14578 (2011).
   PubMedGoogle Scholar
• Lee SW, Markham PF, Coppo MJ et al. Attenuated vaccines can recombine to form virulent field viruses. Science 337, 188 (2012).
   PubMed Web of Science ®Google Scholar
• Romanos MA, Clare JJ, Beesley KM et al. Recombinant Bordetella pertussis pertactin (P69) from the yeast Pichia pastoris: high-level production and immunological properties. Vaccine 9, 901–906 (1991).
   PubMedGoogle Scholar
• Coffman JD, Zhu J, Roach JM, Bavari S, Ulrich RG, Giardina SL. Production and purification of a recombinant Staphylococcal enterotoxin B vaccine candidate expressed in Escherichia coli. Protein Expr. Purif. 24, 302–312 (2002).
   PubMedGoogle Scholar
• Song L, Nakaar V, Kavita U et al. Efficacious recombinant influenza vaccines produced by high yield bacterial expression: a solution to global pandemic and seasonal needs. PLoS ONE 3, e2257 (2008).
   PubMed Web of Science ®Google Scholar
• Cox MM. Recombinant protein vaccines produced in insect cells. Vaccine 30, 1759–1766 (2012).
   PubMed Web of Science ®Google Scholar
• Cunha T, Aires-Barros R. Large-scale extraction of proteins. Mol. Biotechnol. 20, 29–40 (2002).
   PubMed Web of Science ®Google Scholar
• Rigano MM, Walmsley AM. Expression systems and developments in plant-made vaccines. Immunol. Cell Biol. 83, 271–277 (2005).
   PubMedGoogle Scholar
• Dertzbaugh MT. Genetically engineered vaccines: an overview. Plasmid 39, 100–113 (1998).
   PubMedGoogle Scholar
• Yu YZ, Li N, Wang RL, Zhu HQ, Wang S, Yu WY, Sun ZW. Evaluation of a recombinant Hc of Clostridium botulinum neurotoxin serotype F as an effective subunit vaccine. Clin. Vaccine Immunol. 15, 1819–1823 (2008).
   PubMed Web of Science ®Google Scholar
• Patil A, Khanna N. Novel membrane extraction procedure for the purification of hepatitis B surface antigen from Pichia pastoris. J. Chromatogr. B Analyt. Technol. Biomed Life Sci. 898, 7–14 (2012).
   PubMedGoogle Scholar
• Velu V, Nandakumar S, Shanmugam S, Jadhav SS, Kulkarni PS, Thyagarajan SP. Comparison of three different recombinant hepatitis B vaccines: GeneVac-B, Engerix B and Shanvac B in high risk infants born to HBsAg positive mothers in India. World J. Gastroenterol. 13, 3084–3089 (2007).
   PubMed Web of Science ®Google Scholar
• Goldblatt D. Conjugate vaccines. Clin. Exp. Immunol. 119, 1–3 (2000).
   PubMed Web of Science ®Google Scholar
• Pneumococcal conjugate vaccine for childhood immunization –WHO position paper. Wkly Epidemiol. Rec. 82, 93–104 (2007).
   PubMedGoogle Scholar
• Palumbo E, Fiaschi L, Brunelli B, Marchi S, Savino S, Pizza M. Antigen identification starting from the genome: a “reverse vaccinology” approach applied to MenB. Methods Mol. Biol. 799, 361–403 (2012).
   PubMedGoogle Scholar
• Pizza M, Scarlato V, Masignani V et al. Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science 287, 1816–1820 (2000).
   PubMed Web of Science ®Google Scholar
• Rappuoli R. Reverse vaccinology. Curr. Opin. Microbiol. 3, 445–450 (2000).
   PubMed Web of Science ®Google Scholar
• He Y, Xiang Z, Mobley HLT. Vaxign: The first web-based vaccine design program for reverse vaccinology and applications for vaccine development. J. Biomed. Biotechnol. 2010, 297505 (2010).
   PubMedGoogle Scholar
• Liebenberg J, Pretorius A, Faber FE, Collins NE, Allsopp BA, van Kleef M. Identification of Ehrlichia ruminantium proteins that activate cellular immune responses using a reverse vaccinology strategy. Vet. Immunol. Immunopathol. 145, 340–349 (2012).
   PubMedGoogle Scholar
• Lekcharoensuk P, Wiriyarat W, Petcharat N, Lekcharoensuk C, Auewarakul P, Richt JA. Cloned cDNA of A/swine/Iowa/15/1930 internal genes as a candidate backbone for reverse genetics vaccine against influenza A viruses. Vaccine 30, 1453–1459 (2012).
   PubMedGoogle Scholar
• Palmer GH, Brown WC, Noh SM, Brayton KA. Genome-wide screening and identification of antigens for rickettsial vaccine development. FEMS Immunol. Med. Microbiol. 64, 115–119 (2012).
   PubMed Web of Science ®Google Scholar
• Montigiani S, Falugi F, Scarselli M et al. Genomic approach for analysis of surface proteins in Chlamydia pneumoniae. Infect. Immun. 70, 368–379 (2002).
   PubMed Web of Science ®Google Scholar
• Rappuoli R. Reverse vaccinology, a genome-based approach to vaccine development. Vaccine 19, 2688–2691 (2001).
   PubMed Web of Science ®Google Scholar
• Scarselli M, Aricò B, Brunelli B et al. Rational design of a meningococcal antigen inducing broad protective immunity. Sci. Transl. Med. 3, 91ra62 (2011).
   PubMed Web of Science ®Google Scholar
• Dormitzer PR, Ulmer JB, Rappuoli R. Structure-based antigen design: a strategy for next generation vaccines. Trends Biotechnol. 26, 659–667 (2008).
   PubMed Web of Science ®Google Scholar
• Barh D, Misra AN, Kumar A, Vasco A. A novel strategy of epitope design in Neisseria gonorrhoeae. Bioinformation 5, 77–85 (2010).
   PubMedGoogle Scholar
• Croft NP, Purcell AW. Peptidomimetics: modifying peptides in the pursuit of better vaccines. Expert. Rev. Vaccines 10, 211–226 (2011).
   PubMed Web of Science ®Google Scholar
• Thomas S, Thirumalapura NR, Crocquet-Valdes PA, Luxon BA, Walker DH. Structure-based vaccines provide protection in a mouse model of ehrlichiosis. PLoS ONE 6, e27981 (2011).
   PubMedGoogle Scholar
• Dormitzer PR, Grandi G, Rappuoli R. Structural vaccinology starts to deliver. Nat. Rev. Microbiol. 10, 807–813 (2012).
   PubMed Web of Science ®Google Scholar
• Johnson S, Tan L, van der Veen S et al. Design and evaluation of meningococcal vaccines through structure-based modification of host and pathogen molecules. PLoS Pathog. 8, e1002981 (2012).
   PubMed Web of Science ®Google Scholar
• Kwong PD, Shapiro L. Vaccine design reaches the atomic level. Sci. Transl. Med. 3, 91ps29 (2011).
   PubMedGoogle Scholar
• Lauer P, Rinaudo CD, Soriani M et al. Genome analysis reveals pili in group B Streptococcus. Science 309, 105 (2005).
   PubMed Web of Science ®Google Scholar
• Nuccitelli A, Cozzi R, Gourlay LJ et al. Structure-based approach to rationally design a chimeric protein for an effective vaccine against Group B Streptococcus infections. Proc. Natl Acad. Sci. USA 108, 10278–10283 (2011).
   PubMed Web of Science ®Google Scholar
• Harfouche C, Filippini S, Gianfaldoni C et al. RrgB321, a fusion protein of the three variants of the pneumococcal pilus backbone RrgB, is protective in vivo and elicits opsonic antibodies. Infect. Immun. 80, 451–460 (2012).
   PubMed Web of Science ®Google Scholar
• McBride JW, Walker DH. Progress and obstacles in vaccine development for the ehrlichioses. Expert Rev. Vaccines 9, 1071–1082 (2010).
   PubMed Web of Science ®Google Scholar
• Thomas S, Thirumalapura N, Crossley EC, Ismail N, Walker DH. Antigenic protein modifications in Ehrlichia. Parasite Immunol. 31, 296–303 (2009).
   PubMedGoogle Scholar
• Thomas S, Popov VL, Walker DH. Exit mechanisms of the intracellular bacterium Ehrlichia. PLoS ONE 5, e15775 (2010).
   PubMedGoogle Scholar
• Shen AK, Mead PS, Beard CB. The Lyme disease vaccine--a public health perspective. Clin. Infect. Dis. 52( Suppl. 3), s247–s252 (2011).
   PubMed Web of Science ®Google Scholar
• Koide S, Yang X, Huang X, Dunn JJ, Luft BJ. Structure-based design of a second-generation Lyme disease vaccine based on a C-terminal fragment of Borrelia burgdorferi OspA. J. Mol. Biol. 350, 290–299 (2005).
   PubMed Web of Science ®Google Scholar
• Soriani M, Petit P, Grifantini R et al. Exploiting antigenic diversity for vaccine design: the Chlamydia ArtJ paradigm. J. Biol. Chem. 285, 30126–30138 (2010).
   PubMedGoogle Scholar
• Adhikari RP, Karauzum H, Sarwar J et al. Novel structurally designed vaccine for S. aureus α-hemolysin: Protection against bacteremia and pneumonia. PLoS ONE 7, e38567 (2012).
   PubMed Web of Science ®Google Scholar
• Koff WC, Russell ND, Walport M et al. Accelerating the development of a safe and effective HIV vaccine: HIV vaccine case study for the decade of vaccines. Vaccine 31( Suppl. 2), B204–B208 (2013).
   PubMedGoogle Scholar
• Burton DR, Desrosiers RC, Doms RW et al. HIV vaccine design and the neutralizing antibody problem. Nat. Immunol. 5, 233–236 (2004).
   PubMed Web of Science ®Google Scholar
• Burton DR, Stanfield RL, Wilson IA. Antibody vs HIV in a clash of evolutionary titans. Proc. Natl Acad. Sci. USA 102, 14943–14948 (2005).
   PubMed Web of Science ®Google Scholar
• Douek DC, Kwong PD, Nabel GJ. The rational design of an AIDS vaccine. Cell 124, 677–681 (2006).
   PubMed Web of Science ®Google Scholar
• Dey B, Svehla K, Xu L et al. Structure-based stabilization of HIV-1 gp120 enhances humoral immune responses to the induced co-receptor binding site. PLoS Pathog. 5, e1000445 (2009).
   PubMed Web of Science ®Google Scholar
• Pejchal R, Wilson IA. Structure-based vaccine design in HIV: blind men and the elephant? Curr. Pharm. Des. 16, 3744–3753 (2010).
   PubMed Web of Science ®Google Scholar
• Kwong PD, Mascola JR, Nabel GJ. Rational design of vaccines to elicit broadly neutralizing antibodies to HIV-1. Cold Spring Harb. Perspect. Med. 1, a007278 (2011).
   PubMed Web of Science ®Google Scholar
• Falkowska E, Ramos A, Feng Y et al. PGV04, an HIV-1 gp120 CD4 binding site antibody, is broad and potent in neutralization but does not induce conformational changes characteristic of CD4. J. Virol. 86, 4394–403 (2012).
   PubMed Web of Science ®Google Scholar
• Ghiara JB, Ferguson DC, Satterthwait AC, Dyson HJ, Wilson IA. Structure-based design of a constrained peptide mimic of the HIV-1 V3 loop neutralization site. J. Mol. Biol. 266, 31–39 (1997).
   PubMed Web of Science ®Google Scholar
• Stanfield RL, Gorny MK, Williams C, Zolla-Pazner S, Wilson IA. Structural rationale for the broad neutralization of HIV-1 by human monoclonal antibody 447-52D. Structure 12, 193–204 (2004).
   PubMed Web of Science ®Google Scholar
• Zolla-Pazner S. Identifying epitopes of HIV-1 that induce protective antibodies. Nat. Rev. Immunol. 4, 199–210 (2004).
   PubMed Web of Science ®Google Scholar
• Burton DR, Pyati J, Koduri R et al. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 266, 1024–1027 (1994).
   PubMed Web of Science ®Google Scholar
• Zhou T, Xu L, Dey B et al. Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature 445, 732–737 (2007).
   PubMed Web of Science ®Google Scholar
• Wu X, Yang ZY, Li Y et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 329, 856–861 (2010).
   PubMed Web of Science ®Google Scholar
• Zhou T, Georgiev I, Wu X et al. Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science 329, 811–817 (2010).
   PubMed Web of Science ®Google Scholar
• Diskin R, Scheid JF, Marcovecchio PM et al. Increasing the potency and breadth of an HIV antibody by using structure-based rational design. Science 334, 1289–1293 (2011).
   PubMed Web of Science ®Google Scholar
• Zwick MB, Jensen R, Church S et al. Anti-human immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1. J. Virol. 79, 1252–1261 (2005).
   PubMed Web of Science ®Google Scholar
• Correia BE, Ban YE, Holmes MA et al. Computational design of epitope-scaffolds allows induction of antibodies specific for a poorly immunogenic HIV vaccine epitope. Structure 18, 1116–1126 (2010).
   PubMed Web of Science ®Google Scholar
• Nabel GJ, Kwong PD, Mascola JR. Progress in the rational design of an AIDS vaccine. Philos. Trans. R. Soc. Lond., B, Biol. Sci. 366, 2759–2765 (2011).
   PubMed Web of Science ®Google Scholar
• Azoitei ML, Correia BE, Ban YE et al. Computation-guided backbone grafting of a discontinuous motif onto a protein scaffold. Science 334, 373–376 (2011).
   PubMed Web of Science ®Google Scholar
• Riedel T, Ghasparian A, Moehle K, Rusert P, Trkola A, Robinson JA. Synthetic virus like particles and conformationally constrained peptidomimetics in vaccine design. Chembiochem 12, 2829–2836 (2011).
   PubMedGoogle Scholar
• Astronomo RD, Kaltgrad E, Udit AK et al. Defining criteria for oligomannose immunogens for HIV using icosahedral virus capsid scaffolds. Chem. Biol. 17, 357–370 (2010).
   PubMed Web of Science ®Google Scholar
• van Regenmortel MH. Limitations to the structure-based design of HIV-1 vaccine immunogens. J. Mol. Recognit. 24, 741–753 (2011).
   PubMedGoogle Scholar
• van Regenmortel MH. Requirements for empirical immunogenicity trials, rather than structure-based design, for developing an effective HIV vaccine. Arch. Virol. 157, 1–20 (2012).
   PubMedGoogle Scholar
• Liao HX, Lynch R, Zhou T et al. Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. Nature 496, 469–476 (2013).
   PubMed Web of Science ®Google Scholar
• Walker LM, Sok D, Nishimura Y et al. Rapid development of glycan-specific, broad, and potent anti-HIV-1 gp120 neutralizing antibodies in an R5 SIV/HIV chimeric virus infected macaque. Proc. Natl Acad. Sci. USA 108, 20125–20129 (2011).
   PubMed Web of Science ®Google Scholar
• McLellan JS, Pancera M, Carrico C et al. Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature 480, 336–343 (2011).
   PubMed Web of Science ®Google Scholar
• Pejchal R, Doores KJ, Walker LM et al. A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield. Science 334, 1097–103 (2011).
   PubMed Web of Science ®Google Scholar
• Xuan C, Shi Y, Qi J, Zhang W, Xiao H, Gao GF. Structural vaccinology: structure-based design of influenza A virus hemagglutinin subtype-specific subunit vaccines. Protein Cell 2, 997–1005 (2011).
   PubMedGoogle Scholar
• Wilson IA, Skehel JJ, Wiley DC. Structure of the haemagglutinin membrane glycoprotein of influenza virus at 3 A resolution. Nature 289, 366–73 (1981).
   PubMed Web of Science ®Google Scholar
• Akarsu H, Iwatsuki-Horimoto K, Noda T et al. Structure-based design of NS2 mutants for attenuated influenza A virus vaccines. Virus Res. 155, 240–248 (2011).
   PubMedGoogle Scholar
• Kashyap AK, Steel J, Oner AF et al. Combinatorial antibody libraries from survivors of the Turkish H5N1 avian influenza outbreak reveal virus neutralization strategies. Proc. Natl Acad. Sci. USA 105, 5986–5991 (2008).
   PubMed Web of Science ®Google Scholar
• Throsby M, van den Brink E, Jongeneelen M et al. Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells. PLoS ONE 3, e3942 (2008).
   PubMed Web of Science ®Google Scholar
• Ekiert DC, Bhabha G, Elsliger MA et al. Antibody recognition of a highly conserved influenza virus epitope. Science 324, 246–251 (2009).
   PubMed Web of Science ®Google Scholar
• Sui J, Hwang WC, Perez S et al. Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat. Struct. Mol. Biol. 16, 265–273 (2009).
   PubMed Web of Science ®Google Scholar
• Ekiert DC, Friesen RH, Bhabha G et al. A highly conserved neutralizing epitope on group 2 influenza A viruses. Science 333, 843–850 (2011).
   PubMed Web of Science ®Google Scholar
• Corti D, Voss J, Gamblin SJ et al. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science 333, 850–856 (2011).
   PubMed Web of Science ®Google Scholar
• Ekiert DC, Wilson IA. Broadly neutralizing antibodies against influenza virus and prospects for universal therapies. Curr. Opin. Virol. 2, 134–141 (2012).
   PubMed Web of Science ®Google Scholar
• Steel J, Lowen AC, Wang TT et al. Influenza virus vaccine based on the conserved hemagglutinin stalk domain. MBio 1, e00018–10 (2010).
   PubMed Web of Science ®Google Scholar
• Wang TT, Tan GS, Hai R et al. Vaccination with a synthetic peptide from the influenza virus hemagglutinin provides protection against distinct viral subtypes. Proc. Natl Acad. Sci. USA 107, 18979–18984 (2010).
   PubMed Web of Science ®Google Scholar
• Kanekiyo M, Wei CJ, Yassine HM et al. Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies. Nature 499, 102–106 (2013).
   PubMed Web of Science ®Google Scholar
• Stockman LJ, Curns AT, Anderson LJ, Fischer-Langley G. Respiratory syncytial virus-associated hospitalizations among infants and young children in the United States, 1997–2006. Pediatr. Infect. Dis. J. 31, 5–9 (2012).
   PubMed Web of Science ®Google Scholar
• McLellan JS, Yang Y, Graham BS, Kwong PD. Structure of respiratory syncytial virus fusion glycoprotein in the postfusion conformation reveals preservation of neutralizing epitopes. J. Virol. 85, 7788–7796 (2011).
   PubMed Web of Science ®Google Scholar
• Swanson KA, Settembre EC, Shaw CA et al. Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers. Proc. Natl Acad. Sci. USA 108, 9619–9624 (2011).
   PubMed Web of Science ®Google Scholar
• Back JW, Langedijk JP. Structure-based design for high-hanging vaccine fruits. Adv. Immunol. 114, 33–50 (2012).
   PubMedGoogle Scholar